Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Anti-angiogenesis · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AMG 706 | EXPERIMENTAL | AMG 706 QD |
| Name | Type | Description |
|---|---|---|
| Anti-angiogenesis | DRUG | Anti-angiogenesis |
| AMG 706 | DRUG | Anti-angiogenesis |
Inclusion Criteria: Exclusion Criteria:
Top 20 of 45 competitors
Anti-angiogenesis is a small molecule being developed by Amgen Inc. for the treatment of tumors. It is currently in Phase 1 clinical development as an investigational therapy for oncology indications.
Anti-angiogenesis is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. The drug is currently in Phase 1 clinical development for the treatment of tumors.
Anti-angiogenesis is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy in patients with tumors.
Anti-angiogenesis has been studied in one clinical trial, NCT00093873, titled "Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors." This Phase 1 trial was completed and enrolled 71 participants with tumors.
Anti-angiogenesis is also known as AMG 706. The clinical trial NCT00093873, which evaluated the drug in subjects with advanced solid tumors, used the name AMG 706 to refer to the investigational therapy.